How to afford Wegovy when insurance excludes weight-loss drugs (2026)

Why 30% of plans still exclude weight-loss drugs

Despite Wegovy's 2024 FDA approval for cardiovascular risk reduction and a wave of employer coverage expansions through 2025, roughly 30% of US employer plans still carry an exclusion on anti-obesity medications. The exclusion is usually a plan-design decision rather than a medical-necessity decision — which means it isn't appealable through the normal carrier appeals process. Self-funded ERISA plans (most large employers) have the most discretion to exclude.

The first practical step is confirming the exclusion is real. Call member services and ask specifically: 'Does my plan exclude anti-obesity medications as a category, or does it require step therapy I haven't met?' These two answers point to completely different next steps. A category exclusion means no PA will ever work; a step-therapy gap means you can build the documentation and try again.

If your plan does exclude obesity drugs, the next question is whether you have a qualifying cardiovascular indication. Since March 2024, Wegovy carries an FDA-approved indication for cardiovascular risk reduction in adults with BMI ≥27 and established cardiovascular disease. Some plans that exclude obesity coverage still cover Wegovy under the CV indication because it falls under a different formulary category. Confirm specifically with member services before assuming it's blocked.

Manufacturer direct-pay: NovoCare $499/month

Novo Nordisk's NovoCare program sells branded Wegovy at $499 per month to self-pay patients regardless of insurance status. This is the lowest-priced legitimate path to brand Wegovy outside of insurance coverage. The price is per single-dose box (4 weekly pens), and shipping is via NovoCare's mail pharmacy network.

Eligibility is broad: US residents, valid prescription, no insurance billing for the medication. Patients with commercial insurance can use NovoCare if they prefer cash-pay (some choose it because their plan's specialty tier copay exceeds $499, or because they want to bypass the PA process). Patients on Medicare and Medicaid can also use NovoCare — the savings card doesn't work for them, but direct-pay does.

Caveats: NovoCare is brand Wegovy only, not Ozempic. Some patients want the off-label Ozempic prescription because their prescriber prefers it for weight loss; NovoCare doesn't cover that route. Also, NovoCare ships ~5-7 business days, which can disrupt continuity if you let supply run low.

Savings card: $25/month for the commercially insured

The Wegovy savings card brings copays as low as $25/month for patients with commercial insurance — even when the underlying copay is much higher. The card stacks on top of insurance: insurance pays first, the card covers most of the remaining copay up to a monthly cap.

The savings card excludes Medicare, Medicaid, TRICARE, and any other government insurance. If your employer plan converts to Medicare Advantage at retirement, the card stops working that day. Same for VA and TRICARE-eligible patients.

A subtle gotcha: the card is per-prescription, with an annual maximum. Heavy use early in the year can exhaust the cap, leaving full copay exposure later in the year. Verify the annual cap on the card terms before assuming continuous coverage.

HSA and FSA: the tax-advantaged path

GLP-1 medications prescribed for FDA-approved indications qualify as HSA/FSA eligible expenses under IRS Publication 502. If you have an HSA-eligible high-deductible health plan and your plan excludes obesity drugs, paying with HSA dollars effectively gives a 22-37% federal tax discount depending on your bracket, plus state tax savings in most states.

For 2026, the HSA contribution limit is $4,300 for self-only coverage and $8,550 for family coverage. A year of $499/month NovoCare costs $5,988 — fully covered by family HSA contributions if you max out, with significant tax savings versus paying with post-tax dollars.

FSA accounts work similarly but have lower limits and use-it-or-lose-it rules. If you have an FSA, time the contribution to your expected GLP-1 expenses for the plan year. Save receipts: HSA/FSA reimbursement requires proof of qualified medical expense, which a pharmacy receipt provides.

Compounded semaglutide: the legal gray zone in 2026

Compounded semaglutide became widely available during the FDA-declared shortage of brand Wegovy in 2022-2024. The shortage was officially resolved in early 2025, and FDA proposed in April 2026 to permanently remove semaglutide from the 503B bulks list — narrowing the legal pathway for compounding.

As of mid-2026, some 503A pharmacies still compound semaglutide for individual patients under documented medical necessity (allergies to inactive ingredients, dose customization). The legal status is narrower than during the shortage window, and FTC and state boards are actively enforcing against pharmacies that mass-market compounded semaglutide as a cheaper alternative.

If you're considering compounded semaglutide as a cost-saving measure: it is NOT identical to brand Wegovy in formulation, sterility assurance, or post-market surveillance. Adverse-event reporting from compounded products is fragmented. Before switching, ask the prescriber to document the specific clinical reason for compounding rather than brand product.

Realistic budget math: what to actually plan for

If you have commercial insurance with obesity coverage: budget $25-150/month with savings card stacked on insurance. Annual cost: $300-1,800.

If you have commercial insurance with obesity exclusion but want brand: NovoCare $499/month is the floor. Annual cost: $5,988 — fully HSA-deductible.

If you have Medicare without CV indication: brand Wegovy isn't directly accessible at the copay tier. NovoCare direct-pay at $499/month is the realistic option. Annual cost: $5,988, no HSA available on most Medicare plans.

If you have Medicare WITH established cardiovascular disease: many Medicare Part D plans now cover Wegovy under the CV indication. Tier-3 copays of $50-100/month are common. Annual cost: $600-1,200.